BE622612A - - Google Patents
Info
- Publication number
- BE622612A BE622612A BE622612DA BE622612A BE 622612 A BE622612 A BE 622612A BE 622612D A BE622612D A BE 622612DA BE 622612 A BE622612 A BE 622612A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- vaccine
- virus
- add
- buffer solution
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 claims description 19
- 239000000725 suspension Substances 0.000 claims description 13
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims description 12
- 206010044325 trachoma Diseases 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 238000001085 differential centrifugation Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000002155 anti-virotic effect Effects 0.000 claims 1
- 210000002969 egg yolk Anatomy 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000013919 monopotassium glutamate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000061 anti-trachoma effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE622612A true BE622612A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Family
ID=195118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE622612D BE622612A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE622612A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
-
0
- BE BE622612D patent/BE622612A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huber et al. | Lysis of infected myofibers by coxsackievirus B-3-immune T lymphocytes | |
| EP0623167B1 (fr) | Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie | |
| EP0776362A1 (fr) | Procede de preparation du virus grippal, antigens obtenus et leurs applications | |
| CA1277270C (fr) | Procede de culture du virus de la rhinotracheite infectieuse, notamment de la dinde, et vaccin prepare a partir du virus ainsi obtenu | |
| EP0001945B1 (fr) | Nouveaux polysaccharides extraits de corps microbiens d'Haemophilus Influenzae, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
| CH641204A5 (fr) | Substance antitumorale obtenue par culture de mycelium. | |
| EP0041880B1 (fr) | Procédé pour isoler des antigènes glycoprotéiques viraux et son application à la préparation de vaccins | |
| FR2515518A1 (fr) | Procede de production de preparations immunobiologiques applicables pour le diagnostic, la prevention et/ou le traitement d'infections par le candida guilliermondii, et preparations immunobiologiques en resultant | |
| BE622612A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| FR2499410A1 (fr) | Vaccin contre l'avortement enzootique chez les brebis et son procede de preparation | |
| FR2635533A1 (fr) | Procede de fabrication du melange de ribonucleotides | |
| LU86195A1 (fr) | Acylglycannes extraits de klebsiella,leur procede d'obtention,leur application a titre de medicaments et les compositions les renfermant | |
| LU82018A1 (fr) | Vaccins contre des maladies provoquees par des reovirus et procede de preparation de ces vaccins | |
| JPS5852227A (ja) | 淋菌からの免疫原性複合体 | |
| CH625799A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0106831B1 (fr) | Souches modifiées du virus de la diarrhée virale bovine, leur préparation et vaccins les contenant | |
| FR2607392A1 (fr) | Procede pour la preparation d'une souche mutante de bordetella bronchiseptica utile pour la preparation d'un vaccin vivant attenue pour la prophylaxie des infections a b. bronchiseptica et vaccin vivant attenue contre la rhinite atrophique ainsi prepare | |
| BE1003486A5 (fr) | Procede d'obtention de l'inhibiteur de la neuraminidase du virus de la grippe. | |
| FR2731162A1 (fr) | Procede d'extraction d'au moins un actif a partir de cellules vegetales indifferenciees | |
| FR2462166A1 (fr) | Compositions antigeniques, leur preparation et vaccins a base de ces compositions | |
| EP0433127A2 (fr) | Nouveau dérivé sulfaté du galactanne extrait de Klebsiella, procédé de préparation, application à titre de médicaments et compositions pharmaceutiques le renfermant | |
| WO2025070726A1 (ja) | 線維性構造タンパク質の維持又は増加用組成物 | |
| FR2682966A1 (fr) | Preparation d'antigenes et de vaccins du virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie. | |
| BE888635A (fr) | Nouvel extrait de plante, procede de preparation, agent immunostimulant comprenant cet extrait comme composant efficace et immunotherapie par son utilisation, | |
| US1078873A (en) | Substance for treatment of tuberculosis and process of making said substance. |